Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, November 1999, p. 2726-2730, Vol. 43, No. 11
The R. M. Alden Research Laboratory,
Santa Monica-UCLA Medical Center, Santa Monica, California
90404,1 and the UCLA School of Medicine, Los
Angeles, California 900242
Received 1 June 1999/Returned for modification 2 August
1999/Accepted 31 August 1999
The activities of gemifloxacin (SB 265805, LB20304) and comparator
agents were determined by an agar dilution method against 419 clinical
strains of less-commonly identified species of anaerobes. Gemifloxacin
was generally more active than trovafloxacin against gram-positive
strains by one to two dilutions. Peptostreptococci (Peptostreptococcus asaccharolyticus,
Peptostreptococcus magnus, Peptostreptococcus
micros, and Peptostreptococcus prevotii) and Porphyromonas spp. (Porphyromonas
asaccharolytica, Porphyromonas canoris,
Porphyromonas gingivalis, and Porphyromonas
macacae) were all susceptible to
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Activities of Gemifloxacin (SB 265805, LB20304)
Compared to Those of Other Oral Antimicrobial Agents against
Unusual Anaerobes
0.25 µg of gemifloxacin per
ml. The MICs of gemifloxacin at which 90% of the following strains
were inhibited (MIC90s) were
2 µg/ml: Actinomyces
israelii, Actinomyces odontolyticus, Clostridium innocuum, Clostridium
clostridioforme, Anaerobiospirillum spp.,
Bacteroides tectum, Bacteroides ureolyticus,
Bacteroides gracilis (now Campylobacter
gracilis), Prevotella intermedia, Prevotella
heparinolytica, and the Prevotella oris-buccae group. Fusobacterium naviforme and Fusobacterium
necrophorum were also susceptible to
2 µg of gemifloxacin per
ml, while Fusobacterium varium strains exhibited a bimodal
pattern; the other Fusobacterium species, such as
Fusobacterium ulcerans and Fusobacterium
russii, as well as Veillonella spp., the
Prevotella melaninogenica group, Prevotella
bivia, Clostridium difficile, and Bilophila
wadsworthia were relatively resistant to gemifloxacin
(MIC90s,
4 µg/ml).
*
Corresponding author. Mailing address: 2021 Santa
Monica Blvd., Suite 640E, Santa Monica, CA 90404. Phone: (310)
315-1511. Fax: (310) 315-3662. E-mail: EJCGMD{at}aol.com.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»